GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc 6017 Snell Ave, Ste 357, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, firstname.lastname@example.org
Index / US Biomax / Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed / Product Detail : LM482 Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed
#LM482 Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed
Product name : Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed
Catalog number : LM482
Supplier name : US Biomax
Data sheet: Ask more or other datasheet now !
About this Product :Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed antibody storage GENTAUR recommends for long therm storage to freeze at -24 C. For short time storage up to 30 days we suggest fridge storage at 1 to 10 C. Prevent multiple freeze taw cycles of Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed.
Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed storing antibdies for longer storage periods of the Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed we recommend - 21C or lower and for short periods lees than 1 month we suggest +5C fridge temperatures.
More Details about
|Microarray Panel:||Myeloma, lymphoma and normal tissue microarray, containing 10 cases of each myeloma, Hodgkin's lymphoma and large B-cell lymphoma, 8 Burkett's lymphoma, 3 each of follicular Non-Hodgkin's lymphoma and T-cell lymphoma, 4 normal lymph node tissue, single core per case|
|Layout:||8 cols × 6 rows|
|Core Diameter:||2 mm|
|Quality Control:||Anti-Actin confirmed|
|Applications:||Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.|
|Notes:||Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.|
*Tissue Microarray Slide Types:
- Unstained: unstained paraffin tissue microarray slide.
- Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
- H & E: Hematoxylin and Eosin stained tissue microarray slide.
Contact us about this product :
Our team will respond you as soon as possible !
We have also other products like : Myeloma, lymphoma and normal tissue array, 48 cases_48 cores, replaced by LM482a; ihc Anti-Actin confirmed
52062 Aachen Deutschland
Support Karolina Elandt
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
email@example.com | Gentaur
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Finland Helsset +358942419041
Magyarország Budapest +3619980547
US New York+17185132983
WP1019: FAS pathway and Stress induction of HSP regulation
WP1062: Regulation of Actin Cytoskeleton
WP1138: FAS pathway and Stress induction of HSP regulation
WP1178: Regulation of Actin Cytoskeleton
WP1380: Regulation of Actin Cytoskeleton
WP1963: The effect of Glucocorticoids on target gene expression
WP2272: Pathogenic Escherichia coli infection
WP2292: Chemokine signaling pathway
WP314: FAS pathway and Stress induction of HSP regulation
WP351: Regulation of Actin Cytoskeleton
WP51: Regulation of Actin Cytoskeleton
WP511: FAS pathway and Stress induction of HSP regulation
WP523: Regulation of Actin Cytoskeleton
WP571: FAS pathway and Stress induction of HSP regulation
WP788: FAS pathway and Stress induction of HSP regulation
WP824: Regulation of Actin Cytoskeleton
WP89: FAS pathway and Stress induction of HSP regulation
WP902: FAS pathway and Stress induction of HSP regulation
WP944: Regulation of Actin Cytoskeleton
Related Genes :
[FGFR3 JTK4] Fibroblast growth factor receptor 3 (FGFR-3) (EC 188.8.131.52) (CD antigen CD333)
[Adam9 Kiaa0021 Mdc9 Mltng] Disintegrin and metalloproteinase domain-containing protein 9 (ADAM 9) (EC 3.4.24.-) (Meltrin-gamma) (Metalloprotease/disintegrin/cysteine-rich protein 9) (Myeloma cell metalloproteinase)
[XBP1 TREB5 XBP2] X-box-binding protein 1 (XBP-1) (Tax-responsive element-binding protein 5) (TREB-5) [Cleaved into: X-box-binding protein 1, cytoplasmic form; X-box-binding protein 1, luminal form]
[COPS9 MYEOV2] COP9 signalosome complex subunit 9 (CSN acidic protein) (CSNAP) (Myeloma-overexpressed gene 2 protein)
[NR3C1 GRL] Glucocorticoid receptor (GR) (Nuclear receptor subfamily 3 group C member 1)
[Xbp1 Treb5] X-box-binding protein 1 (XBP-1) (Tax-responsive element-binding protein 5) (TREB-5) [Cleaved into: X-box-binding protein 1, cytoplasmic form; X-box-binding protein 1, luminal form]
[CCND1 BCL1 PRAD1] G1/S-specific cyclin-D1 (B-cell lymphoma 1 protein) (BCL-1) (BCL-1 oncogene) (PRAD1 oncogene)
[MET] Hepatocyte growth factor receptor (HGF receptor) (EC 184.108.40.206) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met)
[MTOR FRAP FRAP1 FRAP2 RAFT1 RAPT1] Serine/threonine-protein kinase mTOR (EC 220.127.116.11) (FK506-binding protein 12-rapamycin complex-associated protein 1) (FKBP12-rapamycin complex-associated protein) (Mammalian target of rapamycin) (mTOR) (Mechanistic target of rapamycin) (Rapamycin and FKBP12 target 1) (Rapamycin target protein 1)
[Ighm Igh-6] Ig mu chain C region
[PIK3R1 GRB1] Phosphatidylinositol 3-kinase regulatory subunit alpha (PI3-kinase regulatory subunit alpha) (PI3K regulatory subunit alpha) (PtdIns-3-kinase regulatory subunit alpha) (Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha) (PI3-kinase subunit p85-alpha) (PtdIns-3-kinase regulatory subunit p85-alpha)
[LYN JTK8] Tyrosine-protein kinase Lyn (EC 18.104.22.168) (Lck/Yes-related novel protein tyrosine kinase) (V-yes-1 Yamaguchi sarcoma viral related oncogene homolog) (p53Lyn) (p56Lyn)
[LIG4] DNA ligase 4 (EC 22.214.171.124) (DNA ligase IV) (Polydeoxyribonucleotide synthase [ATP] 4)
[IL6ST] Interleukin-6 receptor subunit beta (IL-6 receptor subunit beta) (IL-6R subunit beta) (IL-6R-beta) (IL-6RB) (CDw130) (Interleukin-6 signal transducer) (Membrane glycoprotein 130) (gp130) (Oncostatin-M receptor subunit alpha) (CD antigen CD130)
[MICA PERB11.1] MHC class I polypeptide-related sequence A (MIC-A)
[MUC1 PUM] Mucin-1 (MUC-1) (Breast carcinoma-associated antigen DF3) (Cancer antigen 15-3) (CA 15-3) (Carcinoma-associated mucin) (Episialin) (H23AG) (Krebs von den Lungen-6) (KL-6) (PEMT) (Peanut-reactive urinary mucin) (PUM) (Polymorphic epithelial mucin) (PEM) (Tumor-associated epithelial membrane antigen) (EMA) (Tumor-associated mucin) (CD antigen CD227) [Cleaved into: Mucin-1 subunit alpha (MUC1-NT) (MUC1-alpha); Mucin-1 subunit beta (MUC1-beta) (MUC1-CT)]
[EIF4E EIF4EL1 EIF4F] Eukaryotic translation initiation factor 4E (eIF-4E) (eIF4E) (eIF-4F 25 kDa subunit) (mRNA cap-binding protein)
[BST2] Bone marrow stromal antigen 2 (BST-2) (HM1.24 antigen) (Tetherin) (CD antigen CD317)
[NUP153] Nuclear pore complex protein Nup153 (153 kDa nucleoporin) (Nucleoporin Nup153)
[Kmt2c Mll3] Histone-lysine N-methyltransferase 2C (Lysine N-methyltransferase 2C) (EC 126.96.36.199) (Myeloid/lymphoid or mixed-lineage leukemia protein 3 homolog)
[IFNAR2 IFNABR IFNARB] Interferon alpha/beta receptor 2 (IFN-R-2) (IFN-alpha binding protein) (IFN-alpha/beta receptor 2) (Interferon alpha binding protein) (Type I interferon receptor 2)
[HPSE HEP HPA HPA1 HPR1 HPSE1 HSE1] Heparanase (EC 188.8.131.52) (Endo-glucoronidase) (Heparanase-1) (Hpa1) [Cleaved into: Heparanase 8 kDa subunit; Heparanase 50 kDa subunit]
[CUL3 KIAA0617] Cullin-3 (CUL-3)
[COPS5 CSN5 JAB1] COP9 signalosome complex subunit 5 (SGN5) (Signalosome subunit 5) (EC 3.4.-.-) (Jun activation domain-binding protein 1)
[IGHA1] Ig alpha-1 chain C region
[MAF] Transcription factor Maf (Proto-oncogene c-Maf) (V-maf musculoaponeurotic fibrosarcoma oncogene homolog)
[CUL1] Cullin-1 (CUL-1)
[Adam15 Mdc15] Disintegrin and metalloproteinase domain-containing protein 15 (ADAM 15) (EC 3.4.24.-) (AD56) (Metalloprotease RGD disintegrin protein) (Metalloproteinase-like, disintegrin-like, and cysteine-rich protein 15) (MDC-15) (Metargidin)
[RPS6KA3 ISPK1 MAPKAPK1B RSK2] Ribosomal protein S6 kinase alpha-3 (S6K-alpha-3) (EC 184.108.40.206) (90 kDa ribosomal protein S6 kinase 3) (p90-RSK 3) (p90RSK3) (Insulin-stimulated protein kinase 1) (ISPK-1) (MAP kinase-activated protein kinase 1b) (MAPK-activated protein kinase 1b) (MAPKAP kinase 1b) (MAPKAPK-1b) (Ribosomal S6 kinase 2) (RSK-2) (pp90RSK2)
[Dbnl Abp1 Sh3p7] Drebrin-like protein (Actin-binding protein 1) (SH3 domain-containing protein 7)
 Could daratumumab be used to treat severe allergy?
 Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union.
 Cryptococcosis in late stage multiple myeloma: consider it.
 Guidelines for screening and management of late and long-term consequences of myeloma and its treatment.
 Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
 Multiple Myeloma Mentorship: Bridging Communication and Educational Gaps .
 Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
 Cytomegalovirus reactivation accompanied by varicella zoster virus reactivation or reinfection in an adult patient of multiple myeloma during bortezomib therapy.
 Chorioretinal folds in a patient with multiple myeloma treated with stem cell transplant.
 Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.
Enter catalog number :